Peptide Research Blog
The latest developments in peptide research, from clinical trial results and regulatory shifts to compound comparisons and emerging industry trends.
Latest Peptide Articles
Are Oral Peptides Here? Inside the Breakthrough and What's Next
Oral semaglutide just proved cardiovascular benefit, Eli Lilly cleared Phase 3, and a microneedle pill raised a billion dollars. Where the oral peptide era actually stands, and what it means for research peptides.
CJC-1295 vs CJC-1295 with DAC: Which One Fits Your Goals?
Two versions of the same peptide, completely different experiences. Here is how to decide which CJC-1295 variant actually fits your lifestyle and goals.
Peptide Therapy for Sleep Optimization: The Quiet Trend Reshaping Recovery in 2026
Peptide therapy is quietly becoming the most promising frontier in sleep science. From DSIP to growth hormone secretagogues, here's how peptides are being studied for deep sleep and recovery.
UPDATE: Retatrutide Clears First Phase 3 Diabetes Trial — 16.8% Weight Loss, 2.0% A1C Drop
Eli Lilly’s triple-agonist retatrutide delivered superior A1C and weight reductions in its first Phase 3 diabetes trial. Full TRANSCEND-T2D-1 breakdown.
GHK vs GHK-Cu: What Changes When Copper Is Added?
GHK and GHK-Cu are the same tripeptide separated by one copper ion. That ion changes stability, gene expression, and nearly every biological effect. Here is the full comparison.
Oral vs Injectable Peptides: Bioavailability and Effectiveness
Oral peptides face massive bioavailability barriers, but real exceptions exist. We break down the evidence for oral semaglutide, BPC-157, collagen peptides, and emerging delivery tech.
Best Peptides for Hair Growth: What Actually Works
GHK-Cu, PTD-DBM, and other peptides for hair growth ranked by research evidence. What the science says, what's proven, and what's still hype.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
Retatrutide Phase 3 Results: 28.7% Weight Loss and Beyond
Eli Lilly's triple-agonist retatrutide delivered record-breaking weight loss in the TRIUMPH-4 trial. Here's what the Phase 3 data means for the future of obesity treatment.
MOTS-c Peptide: Benefits, Mechanism, and What the Research Shows
MOTS-c is the first peptide discovered to be encoded by mitochondrial DNA. New research links it to exercise mimicry, insulin sensitivity, and cellular aging reversal.